<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The purpose of the study was to evaluate the efficacy and tolerability of S-1 monotherapy in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients who have failed the standard <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-based or irinotecan-based chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>From 2007 to 2010, metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients who received S-1 monotherapy as salvage treatment were identified from <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> registry at Samsung Medical Center </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received â‰¥ second-line treatment for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>S-1 was administered orally from day 1 to day 14, every 3 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>The dose of S-1 for each patient was determined according to body surface area (BSA) as follows: for BSA &lt; 1.25 m(2), 80 mg/day; for 1.25 m(2) &lt; BSA &lt; 1.5 m(2), 100 mg/day; and for BSA &gt; 1.5 m(2), 120 mg/day divided by 2 doses </plain></SENT>
<SENT sid="5" pm="."><plain>The median age of the 19 patients was 59 years (range: 33-77) </plain></SENT>
<SENT sid="6" pm="."><plain>Fourteen (73.7%) of 19 patients received S-1 monotherapy as third-line treatment after failing <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-based or irinotecan-based chemotherapy </plain></SENT>
<SENT sid="7" pm="."><plain>Previous regimens prior to S-1 therapy were as follows: FOLFOX, XELOX, FOLFIRI, XELOX + avastin, and cetuximab + irinotecan </plain></SENT>
<SENT sid="8" pm="."><plain>The median number of administered S-1 courses given in the entire studied population was 3 cycles (1-10 cycles) </plain></SENT>
<SENT sid="9" pm="."><plain>Three patients had confirmed partial response (PR) after 3 cycles of S-1 treatment </plain></SENT>
<SENT sid="10" pm="."><plain>After a follow-up duration of 22.3 months (range: 6.7-32.6 months), median time to progression (<z:chebi fb="1" ids="18284">TTP</z:chebi>) was 2.1 (95% CI, 1.8-4.2) months </plain></SENT>
<SENT sid="11" pm="."><plain>Median overall survival was 11.3 months (95% CI, 8.8-16.8) from the time of S-1 chemotherapy administration </plain></SENT>
<SENT sid="12" pm="."><plain>Two patients had grade 1 hand-foot syndrome (HFS) after first and 2nd cycles of treatments, respectively, but treatments were continued without developing further adverse events </plain></SENT>
<SENT sid="13" pm="."><plain>The salvage S-1 monotherapy in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> patients who failed irinotecan-based or <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-based chemotherapy was moderately effective and well tolerated </plain></SENT>
</text></document>